Here, with the FDA-approved CDK4/6 inhibitor, palbociclib, we investigated the efficacy of blockade of Rb signaling against GBM and found out the role of PTEN in the potential of clinically applicable anti-CDK4/6 therapies. This evidence concerns the gene RB1 and glioblastoma.